Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory M Cote

Showing results (1-10 of 92) with videos related to

Pageof 10
Sort By:
Current Reviews in Musculoskeletal Medicine|October 11, 2015
Rank ligand as a target in musculoskeletal neoplasmsGregory M Cote
Current Treatment Options in Oncology|June 11, 2013
Role of epigenetic modulation for the treatment of sarcomaGregory M Cote, Edwin Choy
Hematology/Oncology Clinics of North America|October 8, 2013
Update in treatment and targets in Ewing sarcomaGregory M Cote, Edwin Choy
Current Hematologic Malignancy Reports|April 20, 2011
Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy?Gregory M Cote, George P Canellos
The Oncologist|June 14, 2023
Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal TumorVinayak Venkataraman, Suzanne George, Gregory M Cote
The Oncologist|September 2, 2017
Next-Generation Sequencing for Patients with Sarcoma: A Single Center ExperienceGregory M Cote, Jie He, Edwin Choy
The New England Journal of Medicine|November 30, 2012
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2017
Contemporary Sarcoma Diagnosis, Genetics, and GenomicsInga-Marie Schaefer, Gregory M Cote, Jason L Hornick
The New England Journal of Medicine|March 1, 2013
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
Oncoimmunology|January 23, 2015
Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potentialJacson K Shen, Gregory M Cote, Edwin Choy, et al.
Pageof 10

Showing results (1-10 of 92) with videos related to

Sort By:
Pageof 10
Current Reviews in Musculoskeletal Medicine|October 11, 2015
Rank ligand as a target in musculoskeletal neoplasmsGregory M Cote
Current Treatment Options in Oncology|June 11, 2013
Role of epigenetic modulation for the treatment of sarcomaGregory M Cote, Edwin Choy
Hematology/Oncology Clinics of North America|October 8, 2013
Update in treatment and targets in Ewing sarcomaGregory M Cote, Edwin Choy
Current Hematologic Malignancy Reports|April 20, 2011
Can low-risk, early-stage patients with Hodgkin lymphoma be spared radiotherapy?Gregory M Cote, George P Canellos
The Oncologist|June 14, 2023
Molecular Advances in the Treatment of Advanced Gastrointestinal Stromal TumorVinayak Venkataraman, Suzanne George, Gregory M Cote
The Oncologist|September 2, 2017
Next-Generation Sequencing for Patients with Sarcoma: A Single Center ExperienceGregory M Cote, Jie He, Edwin Choy
The New England Journal of Medicine|November 30, 2012
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2017
Contemporary Sarcoma Diagnosis, Genetics, and GenomicsInga-Marie Schaefer, Gregory M Cote, Jason L Hornick
The New England Journal of Medicine|March 1, 2013
ERBB2 inhibition and heart failureGregory M Cote, Douglas B Sawyer, Bruce A Chabner
Oncoimmunology|January 23, 2015
Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potentialJacson K Shen, Gregory M Cote, Edwin Choy, et al.
Pageof 10